Basic Information
| LncRNA/CircRNA Name | SPRY4-IT1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000281881 |
| Refseq | NR_131221 |
| Regulatory Mechanism | Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | epirubicin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Information of Cancer
| Cancer Name | Breast Cancer |
| ICD-0-3 | C50 |
| Methods | qPCR |
| Sample | Human breast carcinoma cell lines MCF-7 and MDA-MB-231, Breast cancer tissues and the matched normal tissues |
| Expression Pattern | up-regulated |
| Function Description | SPRY4-IT1 was significantly more expressed in cancer tissues than in normal tissues (P<0.05). Increased SPRY4-IT1 expression was significantly correlated with increased rates of lymph node metastasis (P=0.002) and recurrence (P=0.017). Both were independent factors of SPRY4-IT1 expression (P<0.05). High-SPRY4-IT1 patients had significantly lower overall survival and disease-free survival. High SPRY4-IT1 expression indicated poor clinical response in the whole group, luminal A subgroup and luminal B subgroup (P<0.05) and pathological complete response in the whole group. Overexpression of SPRY4-IT1 promoted chemo-resistance of MCF-7 and MDA-MB-231 cells to epirubicin. SPRY4-IT1 has the potential to be a biomarker to predict NACT efficacy and prognosis in breast cancer patients. |
| Pubmed ID | 31638266 |
| Year | 2019 |
| Title | Clinical Significance of SPRY4-IT1 in Efficacy and Survival Prediction in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
External Links
| Links for SPRY4-IT1 | GenBank HGNC Noncode |
| Links for Breast Cancer | Omim Cosmic |